Medical cannabis will be produced and distributed across Europe following a new partnership between cannabidiol (CBD) group Dragonfly Biosciences and a leading cGMP pharmaceutical company in Malta.
The product will be manufactured in a cGMP facility to be exclusively distributed in EU territories where medical cannabis is legally permitted to be sold in pharmacies via prescription.
The new venture takes advantage of Maltese regulatory framework, placing Dragonfly at the forefront of the market for patient treatment through advanced formulations and deliveries.
Commenting on the venture, chief operating officer for Dragonfly Biosciences, Hannah Skingle said: “Combining Dragonfly’s growing and extraction expertise
... read more at: https://www.epmmagazine.com/news/dragonfly-medical/